CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immun...
Saved in:
Main Authors: | Marie José Kersten, Maria Theresa Kuipers |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/12/1/e001157.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01) -
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
by: Chenyun Zhang, et al.
Published: (2025-01-01) -
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
by: Haiying Qin, et al.
Published: (2021-09-01) -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01) -
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)